LT3335728T - Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina - Google Patents

Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina

Info

Publication number
LT3335728T
LT3335728T LTEP18150843.3T LT18150843T LT3335728T LT 3335728 T LT3335728 T LT 3335728T LT 18150843 T LT18150843 T LT 18150843T LT 3335728 T LT3335728 T LT 3335728T
Authority
LT
Lithuania
Prior art keywords
env trimer
stabilized hiv
vaccine
biochemically
biochemically stabilized
Prior art date
Application number
LTEP18150843.3T
Other languages
English (en)
Inventor
Stephen C. Harrison
Bing Chen
Dan H. Barouch
Joseph P. Nikolola
Michael Scott Seaman
Original Assignee
Children`S Medical Center Corporation
Beth Israel Deaconess Medical Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children`S Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc. filed Critical Children`S Medical Center Corporation
Publication of LT3335728T publication Critical patent/LT3335728T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP18150843.3T 2008-10-10 2009-10-13 Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina LT3335728T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10444908P 2008-10-10 2008-10-10

Publications (1)

Publication Number Publication Date
LT3335728T true LT3335728T (lt) 2020-03-10

Family

ID=42101262

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP09820044.7T LT2340038T (lt) 2008-10-10 2009-10-13 Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina
LTEP18150843.3T LT3335728T (lt) 2008-10-10 2009-10-13 Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP09820044.7T LT2340038T (lt) 2008-10-10 2009-10-13 Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina

Country Status (14)

Country Link
US (6) US9707289B2 (lt)
EP (2) EP3335728B8 (lt)
AU (1) AU2009303284B2 (lt)
CY (2) CY1119921T1 (lt)
DK (2) DK2340038T3 (lt)
ES (2) ES2659875T3 (lt)
HR (2) HRP20180281T1 (lt)
HU (2) HUE049393T2 (lt)
LT (2) LT2340038T (lt)
PL (2) PL2340038T3 (lt)
PT (2) PT3335728T (lt)
SI (2) SI2340038T1 (lt)
TR (1) TR201802130T4 (lt)
WO (1) WO2010042942A2 (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2008239628B2 (en) 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
HUE049393T2 (hu) 2008-10-10 2020-09-28 Childrens Medical Center Biokémiailag stabilizált HIV-1 ENV trimer vakcina
JP2013505201A (ja) 2009-04-03 2013-02-14 デューク ユニバーシティー 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物
US9060984B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41
US11149069B2 (en) 2012-08-03 2021-10-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
WO2014107744A1 (en) * 2013-01-07 2014-07-10 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
AU2014224049B2 (en) 2013-02-28 2018-11-29 Therabiol, Inc. HIV antigens and antibodies
US9675687B2 (en) 2013-03-15 2017-06-13 University Of Massachusetts Compositions and methods to treat AIDS
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
EP3052518B1 (en) 2013-10-04 2020-01-08 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
AU2015320574B2 (en) 2014-09-26 2018-12-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against Human Immunodeficiency Virus infection
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
MX2018007198A (es) 2015-12-15 2018-08-01 Janssen Vaccines & Prevention Bv Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
MD3512543T2 (ro) 2016-09-15 2020-11-30 Janssen Vaccines & Prevention Bv Mutații de stabilizare a trimerului proteinei de înveliș HIV
EP3526236A4 (en) 2016-10-17 2020-06-03 Beth Israel Deaconess Medical Center, Inc. SIGNATURE-BASED HUMAN IMMUNODEFICIENCY VIRUS VACCINES (ENV) CONTAINING SIGNS AND METHODS OF USE THEREOF
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
WO2019016062A1 (en) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. HIV ENVELOPE PROTEIN MUTATIONS STABILIZING TRIMERIC FORM
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2020064621A1 (en) 2018-09-25 2020-04-02 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11857619B2 (en) 2019-11-07 2024-01-02 Janssen Vaccines & Prevention B.V. Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) * 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
CA2505583C (en) * 2002-12-03 2014-07-15 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
WO2005052119A2 (en) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
WO2006002079A2 (en) * 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
ATE527281T1 (de) * 2004-07-16 2011-10-15 Us Gov Health & Human Serv Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
CA2583843C (en) 2004-10-13 2010-09-21 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
US20100221241A1 (en) * 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP2040747A4 (en) 2006-06-19 2010-08-25 Progenics Pharm Inc SOLUBLE STABILIZED TRIMERIC HIV ENV PROTEINS AND USES THEREOF
CA2667358A1 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
HUE049393T2 (hu) 2008-10-10 2020-09-28 Childrens Medical Center Biokémiailag stabilizált HIV-1 ENV trimer vakcina
BRPI0921588B1 (pt) 2008-11-18 2021-12-28 Beth Israel Deaconess Medical Center Vacina compreendendo um polipeptídeo viral e seu método de preparação, kit e uso do polipeptídeo viral
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
WO2012030904A2 (en) 2010-08-31 2012-03-08 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013055908A1 (en) 2011-10-12 2013-04-18 The Scripps Research Institute An hiv-1 gp120 mini v3 loop and uses thereof
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
SG11201503864TA (en) 2012-11-16 2015-06-29 Beth Israel Hospital Recombinant adenoviruses and use thereof
WO2014107744A1 (en) * 2013-01-07 2014-07-10 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CN105518022B (zh) * 2013-07-08 2020-08-18 诺华股份有限公司 具有嵌合表面蛋白的轮状病毒颗粒
WO2015048770A2 (en) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10444908B2 (en) 2016-12-31 2019-10-15 Innoventions, Inc. Virtual touchpads for wearable and portable devices

Also Published As

Publication number Publication date
HUE037270T2 (hu) 2018-08-28
PT3335728T (pt) 2020-02-19
TR201802130T4 (tr) 2018-03-21
ES2659875T3 (es) 2018-03-19
US9950060B2 (en) 2018-04-24
DK2340038T3 (en) 2018-02-26
EP3335728B1 (en) 2019-12-25
US20190240319A1 (en) 2019-08-08
EP3335728A1 (en) 2018-06-20
US10307478B2 (en) 2019-06-04
PL3335728T3 (pl) 2020-06-29
US20200323976A1 (en) 2020-10-15
AU2009303284A1 (en) 2010-04-15
EP2340038B1 (en) 2018-01-10
US20180207259A1 (en) 2018-07-26
US20120045472A1 (en) 2012-02-23
CY1119921T1 (el) 2018-12-12
WO2010042942A3 (en) 2010-06-24
US11229696B2 (en) 2022-01-25
US9707289B2 (en) 2017-07-18
PT2340038T (pt) 2018-02-21
HUE049393T2 (hu) 2020-09-28
ES2765890T3 (es) 2020-06-11
AU2009303284B2 (en) 2016-01-28
PL2340038T3 (pl) 2018-07-31
US20200023056A1 (en) 2020-01-23
CY1122745T1 (el) 2021-01-27
LT2340038T (lt) 2018-04-10
US10463729B2 (en) 2019-11-05
SI2340038T1 (en) 2018-05-31
US10653770B2 (en) 2020-05-19
EP2340038A4 (en) 2012-08-15
HRP20200370T1 (hr) 2020-06-12
WO2010042942A2 (en) 2010-04-15
DK3335728T3 (da) 2020-02-24
EP2340038A2 (en) 2011-07-06
HRP20180281T1 (hr) 2018-05-04
SI3335728T1 (sl) 2020-04-30
EP3335728B8 (en) 2020-03-11
US20170290907A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
EP2340038A4 (en) BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE
IL217008A0 (en) Vaccine
GB0810305D0 (en) Influenza vaccination
HRP20151124T1 (en) Vaccine
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
GB0822001D0 (en) Vaccine
IL222228A0 (en) Hiv vaccine
IL212311A0 (en) Immunoenhancer-linked oligomeric hiv vaccines
EP2588211A4 (en) EPS TRIMER-IMMUNOGENIC
GB201006165D0 (en) Vaccine
GB0810710D0 (en) Vaccine
GB0918679D0 (en) Influenza vaccine
GB0816284D0 (en) Vaccine
ZA201100962B (en) Influenza vaccines
IL216102A0 (en) Combined measles-malaria vaccine
GB0816447D0 (en) Vaccine
GB201000522D0 (en) Vaccine
EP2424879A4 (en) INFLUENZA VACCINE
IL217194A0 (en) Vaccine
EP2240199A4 (en) INFLUENZA VACCINES
ZA201107971B (en) Combined measles-malaria vaccine
GB0914545D0 (en) Vaccine
GB0806461D0 (en) Anti-atheroma vaccine
GB0809781D0 (en) Vaccine
GB0810215D0 (en) Vaccine